Dupuytren Disease Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | 180 Life Sciences, Ventoux Biosciences

As per DelveInsight, the Dupuytren Disease Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Dupuytren Disease and the launch of new therapies in the market.

DelveInsight's "Dupuytren Disease Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dupuytren Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Dupuytren Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dupuytren Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Dupuytren Disease: An Overview
Dupuytren disease or Dupuytren's Contracture also known as Palmar Fibromatosis, is a benign fibroproliferative disorder in which subcutaneous fibrous nodules arise within the palmar fascia of the hand, eventually forming cord like attachments with the adjacent flexor tendons. One of the earliest classifications of Dupuytren's disease according to the histological appearance using optical microscopy described three stages: proliferative, involutional, and residual.

The development of the condition usually occurs quite slowly over many months, or even years, though in rare cases it can develop suddenly. Often the first sign of the condition is a painless lump or nodule in the palm near the base of the fingers. This may be followed by a feeling of tightness and/or tenderness in the fingers. As the condition progresses it is difficult to fully straighten the fingers and there may be dimpling and puckering of the skin over the area. Eventually, contracture of the fingers may become so severe that they cannot be used.

Currently, physical examination of the hands is the gold standard for assessment of disease stage, disease extent, and disease progression. Ultrasound (US) depicts echogenicity and is well suited to reveal the dimensions of a soft tissue lesion in the sagittal and transverse plane. With computed tomography (CT) and magnetic resonance imaging (MRI), three dimensions of soft tissue lesions can be displayed in detail.

Dupuytren Disease Market Key Facts
• According to the Dupuytren Research Group, approximately 15 million Americans, aged 35 or over, have the disorder if those experiencing early signs are counted.
• According to Ball et al., (2016), in the UK the prevalence of Dupuytren's disease in the general population increases with age, and it was estimated as 12% in those aged 55 years, rising to 29% in those aged 75 years in the general population.
• As per the National Institute for Health and Care Excellence (NICE), in the UK, the prevalence of Dupuytren's disease ranges from 0.2-30%, varying widely possibly due to genetics, environment, or a combination of both. It is more common in men than women. About 1 in 6 men in the UK over the age of 65 have some degree of Dupuytren's contracture.
• Dupuytren's disease is a common fibroproliferative disorder of the hand, affecting approximately 4% of the general UK and US populations (Ball et al., 2016).

Get a Detailed Overview of the Evolving Dupuytren Disease Market Trends @
https://www.delveinsight.com/report-store/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dupuytren Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dupuytren Disease therapies in the market. It also provides a detailed assessment of the Dupuytren Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Dupuytren Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Dupuytren Disease Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dupuytren Disease Epidemiology
The epidemiology section covers detailed insights into the historical, and current Dupuytren Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Dupuytren Disease Epidemiology Segmented as -
• Total Prevalent Cases of Dupuytren's Contracture in the 7MM [2019-2032]
• Treated Cases of Dupuytren's Contracture in the 7MM [2019-2032]
• Diagnosed Cases of Dupuytren's Contracture in the 7MM [2019-2032]
• Age-specific Cases of Dupuytren's Contracture in the 7MM [2019-2032]
• Gender-specific Cases of Dupuytren's Contracture in the 7MM [2019-2032]

Dupuytren Disease Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dupuytren Disease market or expected to be launched during the study period. The analysis covers the market share by Dupuytren Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Dupuytren Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Dupuytren Disease Market @
https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dupuytren Disease Therapeutics Assessment
Currently, there is no highly effective treatment to stop Dupuytren from getting worse, leaving surgery as the only viable option as the disease progresses. Surgery is considered if a finger has lost 30° of the metatarsophalangeal joint or any proximal interphalangeal joint extension. Surgery is not advocated in early Dupuytren disease except when it is associated with persistent pain, especially at night.

Dupuytren's Contracture is not comprehensively studied, therefore, the emerging landscape of this condition is not very robust. It has been observed that very few trials have been registered for this indication.

180 Life Sciences has initiated a special clinical program for preventing Duptyren's finger and hand contracture before it becomes severe and permanent or requires surgery. The drug is currently in Phase IIb/III of clinical trials, which are designed to evaluate both dosing requirements and efficacy in patients with the disease. 180 Life Sciences was granted a US patent for the treatment of Dupuytren's disease, along with several other patents. A successful therapeutic for a large market such as Dupuytren's could conceivably reach blockbuster status.

The company was granted a US patent for the treatment of Dupuytren's disease as well. The research is being conducted in collaboration with the University of Oxford and 180 Life Sciences and is funded by the Welcome Trust and the UK Department of Health.

Learn More About the Emerging Therapies and key Companies in the Dupuytren Disease Therapeutics Market @
https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dupuytren Disease Competitive Intelligence Analysis
4. Dupuytren Disease Market Overview at a Glance
5. Dupuytren Disease Background and Overview
6. Dupuytren Disease Patient Journey
7. Dupuytren Disease Epidemiology and Patient Population
8. Dupuytren Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Dupuytren Disease Unmet Needs
10. Key Endpoints of Dupuytren Disease Treatment
11. Dupuytren Disease Marketed Products
12. Dupuytren Disease Emerging Therapies
13. Dupuytren Disease Seven Major Market Analysis
14. Attribute Analysis
15. Dupuytren Disease Market Outlook (7 major markets)
16. Dupuytren Disease Access and Reimbursement Overview
17. KOL Views on the Dupuytren Disease Market.
18. Dupuytren Disease Market Drivers
19. Dupuytren Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/dupuytrens-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.